PARP inhibitors synergize with abiraterone
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0060-9
Abstract: Poly(ADPribose) polymerase (PARP) inhibitors have been previously shown to improve the outcomes of patients with BRCAmutant prostate cancer. Now, data from a phase II study demonstrate that the PARP inhibitor olaparib, in combination with abiraterone,… read more here.
Keywords: parp inhibitors; abiraterone plus; synergize abiraterone; inhibitors synergize ... See more keywords